News
VRAX
0.6273
+2.18%
0.0134
Weekly Report: what happened at VRAX last week (0429-0503)?
Weekly Report · 11h ago
Weekly Report: what happened at VRAX last week (0422-0426)?
Weekly Report · 04/29 11:15
Virax Biolabs Debuts ImmuneSelect Portfolio
TipRanks · 04/25 12:58
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Processa Pharma (NASDAQ:PCSA) shares moved upwards by 31.2% to $2.12 during Thursday's pre-market session. Cyclacel Pharmaceuticals stock rose 23.04% and Compass Therapeutics shares rose 21.62%. Can Fite Biofarma (AMEX:CANF) stock also moved upwards.
Benzinga · 04/25 12:06
EXCLUSIVE: Virax Biolabs Launches Immune Profiling Solutions To Evaluate Adaptive Immunity In Post-Viral Syndromes
Virax Biolabs launches 'ImmuneSelect' for post-viral syndromes. The ImmuneSelect portfolio includes peptide pools for SARS-CoV-2, Lyme Disease, and Epstein-Barr Virus. The products are for research and investigational use only and not intended to be used as a diagnostic tool.
Benzinga · 04/25 11:45
Weekly Report: what happened at VRAX last week (0415-0419)?
Weekly Report · 04/22 11:04
12 Health Care Stocks Moving In Wednesday's After-Market Session
Trevena (NASDAQ:TRVN) shares increased by 27.0% to $0.51 during Wednesday's after-market session. Mustang Bio stock increased by 11.97% and SINTX Techs stock rose 10.32% in the same session. Losers TRACON Pharma and DIH Holding US stock fell by 16.6% and 14.05% respectively.
Benzinga · 04/17 20:31
Virax Biolabs Showcases Innovations at ESCMID 2024
TipRanks · 04/16 11:57
Weekly Report: what happened at VRAX last week (0408-0412)?
Weekly Report · 04/15 10:57
Weekly Report: what happened at VRAX last week (0401-0405)?
Weekly Report · 04/08 11:01
Weekly Report: what happened at VRAX last week (0325-0329)?
Weekly Report · 04/01 10:59
Weekly Report: what happened at VRAX last week (0318-0322)?
Weekly Report · 03/25 11:02
Weekly Report: what happened at VRAX last week (0311-0315)?
Weekly Report · 03/18 11:01
Virax Biolabs receives Nasdaq notification letter regarding minimum bid price deficiency
Healthcare Virax Biolabs receives Nasdaq notification letter regarding minimum bid price deficiency Mar. 15, 2024 4:34 PM ETVirax Biol Labs Group Limited (VRAX) Stock. Nasdaq notifies company that it is not in compliance with minimum bid prices requirement.
Seeking Alpha · 03/15 20:34
Virax Biolabs Announces Receipt If NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
Virax Biolabs Group Limited is not in compliance with the minimum bid price requirement for continued listing on the Nasdaq. The Nasdaq requires listed securities to maintain a minimum price of $1.00 per share. Virax is focused on the detection of immune responses and diagnosis of viral diseases.
Benzinga · 03/15 20:31
Weekly Report: what happened at VRAX last week (0304-0308)?
Weekly Report · 03/11 10:58
Weekly Report: what happened at VRAX last week (0226-0301)?
Weekly Report · 03/04 11:00
Weekly Report: what happened at VRAX last week (0219-0223)?
Weekly Report · 02/26 11:12
12 Health Care Stocks Moving In Friday's After-Market Session
Ocean Biomedical (NASDAQ:OCEA) stock rose 37.6% to $2.16 during Friday's after-market session. The company's market cap stands at $73.6 million. NeuBase Therapeutics and Virax Biolabs Group also moved upwards. Losers include Telesis Bio and Celularity.
Benzinga · 02/23 21:31
12 Health Care Stocks Moving In Thursday's After-Market Session
Telesis Bio (NASDAQ:TBIO) shares rose 114.3% to $0.97 during Thursday's after-market session. Maravai LifeSciences shares rose 17.41% as the company's Q4 earnings report came out today. Aesthetic Medical Intl stock rose 11.89% and Outlook Therapeutics stock moved upwards by 8.22%.
Benzinga · 02/22 21:31
More
Webull provides a variety of real-time VRAX stock news. You can receive the latest news about Virax Biolabs Group Ltd through multiple platforms. This information may help you make smarter investment decisions.
About VRAX
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing a T-Cell Test technologies with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against global viral threats. Its product portfolio includes ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.